scholarly journals COVID-19 vaccine causing Guillain barre syndrome, a rare potential side effect

2021 ◽  
Author(s):  
ahmad matarneh ◽  
alia al-battah ◽  
khalid farooqui ◽  
mohamed ghamoodi ◽  
Mohammed alhatou
Keyword(s):  
Side Effect ◽  
Guillain Barre Syndrome ◽  
Variable Degree ◽  
Potential Side Effect ◽  
The World ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

COVID-19 Virus has affected the world in many ways, resulting in several challenges. COVID 19 vaccines were introduced recently, with a variable degree of immunogenicity and safety. We report a 61-year-old man who had GBS a few days after Receiving The vaccine, his condition improved after 5 days of IVIG

scholarly journals COVID‐19 vaccine causing Guillain‐Barre syndrome, a rare potential side effect

2021 ◽  
Vol 9 (9) ◽  
Author(s):  
Ahmad S. Matarneh ◽  
Alia Hani Al‐battah ◽  
Khalid Farooqui ◽  
Mohamed Ghamoodi ◽  
Mohammed Alhatou
Keyword(s):  
Side Effect ◽  
Guillain Barre Syndrome ◽  
Potential Side Effect ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

History of acute polyradiculoneuropathy (part 2)

Neurology ◽  
2020 ◽  
Vol 94 (19) ◽  
pp. 836-840
Author(s):  
Stéphane Mathis ◽  
Antoine Soulages ◽  
Gwendal Le Masson ◽  
Jean-Michel Vallat
Keyword(s):  
Clinical Entity ◽  
Guillain Barre Syndrome ◽  
Great War ◽  
The World ◽  
Guillain Barré Syndrome ◽  
History Of ◽  
The Rich ◽  
Guillain Barré ◽  
The Great War ◽  
Rich History

First reported by Guillain, Barré, and Strohl during the Great War, the concept of “Guillain-Barré syndrome” (GBS) progressively emerged as a clinical entity in its own right. Despite many debates about its clinical and pathophysiologic characteristics, GBS is now recognized as a disease throughout the world. We describe here the main steps of the rich history of GBS, from 1916 to the present.

scholarly journals Atypical facial onset Guillain-Barré syndrome following first dose of COVISHIELD vaccine

2021 ◽  
Vol 20 (3) ◽  
pp. 379-382
Author(s):  
R.V. Aravinda ◽  
◽  
Priyanka Mahendra Tater ◽  
Harsha Huliyappa ◽  
Christy Joseph Manual ◽  
...  
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Guillain Barre Syndrome ◽  
Significant Morbidity ◽  
Global Pandemic ◽  
The World ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

In the midst of the global pandemic of COVID-19 and its significant morbidity and mortality reported across the world due to severe acute respiratory distress syndrome (SARS), it has always been posing a new set of complications each passing day. As we are still in the process of understanding about the complications related to COVID-19, we are encountered with complications related to immunization for COVID-19. We are reporting a case of facial onset Guillain-Barré syndrome (GBS) in the patient who received first dose of COVISHIELD vaccine a couple of weeks prior to the onset of his illness.

scholarly journals SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms

2021 ◽  
Vol 12 ◽  
Author(s):  
Shahrzad Shoraka ◽  
Maria Lucia Brito Ferreira ◽  
Seyed Reza Mohebbi ◽  
Amir Ghaemi
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Respiratory System ◽  
Respiratory Symptoms ◽  
Guillain Barre Syndrome ◽  
New Disease ◽  
Neurological Manifestations ◽  
Pathogenic Mechanisms ◽  
The World ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Since December 2019, the world has been facing an outbreak of a new disease called coronavirus disease 2019 (COVID-19). The COVID-19 pandemic is caused by a novel beta-coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 infection mainly affects the respiratory system. Recently, there have been some reports of extra-respiratory symptoms such as neurological manifestations in COVID-19. According to the increasing reports of Guillain-Barré syndrome following COVID-19, we mainly focused on SARS-CoV-2 infection and Guillain-Barré syndrome in this review. We tried to explain the possibility of a relationship between SARS-CoV-2 infection and Guillain-Barré syndrome and potential pathogenic mechanisms based on current and past knowledge.

scholarly journals Guillain-Barré Syndrome after COVID-19 Vaccine: Should We Assume a Causal Link?

2021 ◽  
pp. 20-24
Author(s):  
Santvana Kohli ◽  
Mudit Varshney ◽  
Sandeep Mangla ◽  
Binita Jaiswal ◽  
Priyanka H. Chhabra
Keyword(s):  
World Wide ◽  
Economic Status ◽  
Neurological Complications ◽  
Causal Link ◽  
Guillain Barre Syndrome ◽  
Disease Spectrum ◽  
The World ◽  
Guillain Barré Syndrome ◽  
Mass Immunization ◽  
Guillain Barré

The virus SARS-CoV2 and the disease spectrum caused by it have led to a widespread impact on the medical and economic status of all nations of the world. This led to an expedited mission to introduce a vaccine which could attempt to neutralize the pandemic to some extent. Many vaccines have been introduced with an acceptable safety profile, producing only mild adverse effects of soreness at injection site, malaise, fever, diarrhoea, myalgia and uncommonly allergic/anaphylactic reactions and possibility of getting infected with SARS-CoV2. Some isolated reports have also emerged of serious thromboembolic phenomena and neurological complications such as Guillain-Barré Syndrome (GBS). A similar incident was noticed at our institute, where a 71 year old male recipient of COVID-19 vaccine at an immunization centre, presented to us with features of GBS. We hereby report this case, not establishing a direct link between the two, but to raise awareness regarding the ongoing mass immunization world-wide.

scholarly journals Guillain-Barre Syndrome Following Ad26.Cov2.S Covid-19 Vaccine: A Case Report

2021 ◽  
Vol 10 (2) ◽  
pp. 63-64
Author(s):  
Sushmita Khanal ◽  
Sunil Babu Khanal
Keyword(s):  
Case Report ◽  
Side Effect ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Rare Side Effect ◽  
Guillain Barré

Guillain-Barre Syndrome has been reported as a rare side effect in the recipients of Johnson & Johnson®'s Janssen Ad26.COV2.S COVID-19 vaccine. We report a case of Guillain-Barre Syndrome in a 50 years old female following the administration of the aforementioned vaccine.

scholarly journals Management of Guillain-Barré Syndrome

2019 ◽  
Vol 06 (02) ◽  
pp. 160-166
Author(s):  
Kadarapura N. Gopalakrishna ◽  
Venkatapura J. Ramesh
Keyword(s):  
Guillain Barre Syndrome ◽  
Variable Degree ◽  
Motor Weakness ◽  
Immune Mediated ◽  
Autonomic Disturbance ◽  
Sensory Features ◽  
Guillain Barré Syndrome ◽  
Acute Polyneuropathy ◽  
Guillain Barré ◽  
Csf Examination

AbstractGuillain-Barré syndrome (GBS) is the most common, immune-mediated acute polyneuropathy characterized by variable degree of motor weakness, often presenting with quadriparesis. GBS with respiratory failure requiring endotracheal intubation with mechanical ventilation is common, affecting approximately 30% of patients. In addition, they present with sensory features, cranial nerve involvement, and autonomic disturbance. The majority of GBS patients have preceding respiratory tract infection or gastroenteritis. The diagnosis of GBS is based on clinical features supported by cerebrospinal fluid (CSF) examination and nerve conduction studies. Early course of the GBS requires meticulous monitoring and early initiation of immunotherapy. Plasma exchange (PE) and intravenous immunoglobulin (IVIg) are the proven therapies, and both have been shown to be equally effective. General supportive care is an important part of management of GBS. A multidisciplinary approach to prevent and manage potential complications in rapidly progressing GBS is important to reduce morbidity and mortality.

Sign in / Sign up

Export Citation Format

Share Document